SCHEMBL6094859

SCHEMBL6094859

COc1cc(CBr)cc(-c2cccs2)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TNFRSF1A P19438 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 1/20 0.46
HSD17B10 Q99714 1/20 0.46
RPS6KB2 Q9UBS0 2/20 0.43
TUBB4A P04350 4/20 0.43
TUBB P07437 4/20 0.43
TUBA3C P0DPH7 4/20 0.43
TUBA1B P68363 4/20 0.43
TUBA4A P68366 4/20 0.43
TUBB4B P68371 4/20 0.43
TUBB3 Q13509 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090955 0.87 TNFRSF1A (0.47) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6094543 0.84 HTR7 (0.47) ALDH1A1SMN1; SMN2TNFRSF1AKDM4EHPGD
SCHEMBL6092943 0.77 TNFRSF1A (0.52) ALDH1A1SMN1; SMN2TNFRSF1AKDM4EHPGD
SCHEMBL7212822 0.76 RPS6KB2 (0.49) CYP1A2ALDH1A1SMN1; SMN2TNFRSF1AKDM4E
SCHEMBL6092788 0.76 MAPT (0.50) ALDH1A1SMN1; SMN2TNFRSF1AKDM4EHPGD
SCHEMBL6040526 0.75 TNFRSF1A (0.55) CYP3A4ALDH1A1SMN1; SMN2TNFRSF1AKDM4E
SCHEMBL29143294 0.75 TUBB4A (0.45) ALDH1A1KDM4EHPGDGAATUBB4A
SCHEMBL28672054 0.74 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2TNFRSF1AKDM4EHPGD
SCHEMBL2780877 0.73 RPS6KB2 (0.56) ALDH1A1SMN1; SMN2TNFRSF1AKDM4EHPGD
SCHEMBL6989686 0.73 TNFRSF1A (0.56) CYP3A4ALDH1A1SMN1; SMN2TNFRSF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 CYP1A2 38/4885CYP3A4 51/4885CYP2D6 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.